The Life Sciences Industry in Norway is looking to triple its exports by 2030. With major investments going into both R&D and production, a growing number of life science companies are in the making or already growing their portfolio. If you are looking for investment opportunities in life sciences, now is the time to look to Norway.

At the Cutting Edge Festival, one of Norway’s leading tech festivals, we had several cluster members pitching their solutions to investors and visitors. The Cutting Edge Festival was all about the big challenges we face in the world today. Our members are all about the solutions. If you missed this session, and want to learn more, you will find a small snapshot of each of their pitches below.

Snapshot of pitches.

The first runner up was Algavida AS, a micro-algae production company. They are moving from pilot to a demonstration plant at the Maarud Farm and Woods factory in Norway to produce algae powder and extractives. Algae ingredients are known for their benefits in health products and feed. Algavida is targeting the aqua feed market due to the high demand and high prices for extractives, a demand set to increase in the future as safe and clean aqua feed ingredients are key for sustainable fisheries. They are looking to raise 10 MNOK for their demonstration plant. You may reach out to to request a meeting.

The next company pitching was Age Labs, a company that focus on detecting age related diseases at an early stage. Age related diseases are usually detected too late, making them hard to treat effectively. We know that the probability for disease increase as we get older, and early diagnosis is of vital importance. Age Labs is developing an easy to use, reliable and affordable solution: a blood test for early diagnosis. Their solution enables earlier treatment and earlier lifestyle interventions. They are now looking for more private investors, and you may contact for further information. 

Another exciting company to look out for is Kappa BioScience. Kappa BioScience has the vision to deliver vitamin K2 to the mass market, making it available to everybody, everywhere. Why is K2 important? First of all, our diets do not provide us with enough so it needs to be supplemented for optimal bone and hearth health. Secondly, it balances calcium. With adequate vitamin K2 intake, calcium is directed toward the bones, and away from arteries. This reduces the risk of heart disease and strengthen healthy bones simultaneously. Kappa BioScience is the first to develop K2Vital, currently the global leader in vitamin K2. They are building their second factory in Norway, and claim to be the only ones who can make this production affordable. Contact for more info.

Let’s dive into the ocean and all the opportunities it entails. Only 5% of our food comes from the ocean, and this is where the future food supply is likely to originate. For continued growth of the aquaculture sector, we are dependent on efficient vaccines. PHARMAQ, part of Zoetis, is a company specialising in vaccines and innovation for aquaculture. With more than 30 years of experience in dealing with fish health and prevention of disease, they have developed more than 35 different vaccines and is a force to be reckoned with. Efficient vaccines are important for the sustainable growth of the industry. With 7 out of 10 farmed salmon  vaccinated with PHARMAQ products, we are on the right track for sustainable food production using less antibiotics. Fun fact: did you know that less than one percent of Norwegian salmon is treated with antibiotics? Contact if you want to learn more about PHARMAQ’s products.

The next company, Genetic Analysis AS, is an Oslo-based in-vitro diagnostic company spinning out from Ås University. Out of the one thousand known microbial species in the human gut, GA is measuring specific sets of bacteria and test whether there are in balance or not in comparison to a reference healthy population. A dysbiosis – a microbial imbalance – plays an important role on your health condition. GA has developed the GA-Map® dysbiosis test for microbiota profiling. This is the first dysbiosis test which is commercially available, standardised, CE-marked and clinically validated. Clinical applications are diagnosis, treatment prediction, monitoring, disease severity course in gastrointestinal diseases (IBS – irritable bowel syndrome – and IBD – inflammatory bowel disease). IBS alone has a prevalence of 10 – 15 % in the western world, with only half having been diagnosed so far. Contact Bruno Mainnemard Øijordsbakken at for further information.

The last one pitching was Inventas, a product design agency. They are offering a process named Sprint for the development of products within med-tech and other areas. It is a comprehensive one-week process taking you through all the steps necessary to move forward with your design. Using design thinking combined with their competencies in mechanics, electronics, robotics and all things digital, they offer clients a fast-phased journey to their desired end product. That could be visualisations, mock-ups, prototypes, mapping, concepts, business models or reports with insights about next steps. Contact for more details.

Want help in setting up a meeting, or need more info? Feel free to contact the members directly, or The Life Science Cluster at


Share This